NASDAQ:NBRV - Nabriva Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.97 -0.01 (-0.51 %) (As of 01/20/2019 03:50 PM ET)Previous Close$1.97Today's Range$1.95 - $2.0052-Week Range$1.12 - $6.94Volume225,075 shsAverage Volume775,154 shsMarket Capitalization$1.32 billionP/E Ratio-0.79Dividend YieldN/ABeta1.97 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Receive NBRV News and Ratings via Email Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV Previous Symbol CUSIPN/A Webwww.nabriva.com Phone610-816-6640Debt Debt-to-Equity Ratio0.01 Current Ratio7.35 Quick Ratio7.35Price-To-Earnings Trailing P/E Ratio-0.79 Forward P/E Ratio-1.00 P/E GrowthN/A Sales & Book Value Annual Sales$5.32 million Price / Sales248.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book0.88Profitability EPS (Most Recent Fiscal Year)($2.49) Net Income$-74,350,000.00 Net Margins-1,064.19% Return on Equity-87.03% Return on Assets-75.17%Miscellaneous Employees88 Outstanding Shares669,820,000Market Cap$1.32 billion OptionableOptionable Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.03. The biotechnology company earned $0.46 million during the quarter, compared to analysts' expectations of $3.27 million. Nabriva Therapeutics had a negative net margin of 1,064.19% and a negative return on equity of 87.03%. View Nabriva Therapeutics' Earnings History. When is Nabriva Therapeutics' next earnings date? Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Nabriva Therapeutics. What price target have analysts set for NBRV? 7 brokerages have issued twelve-month price objectives for Nabriva Therapeutics' stock. Their predictions range from $5.00 to $18.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $11.60 in the next year. This suggests a possible upside of 488.8% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics. What is the consensus analysts' recommendation for Nabriva Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics. What are Wall Street analysts saying about Nabriva Therapeutics stock? Here are some recent quotes from research analysts about Nabriva Therapeutics stock: 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (1/18/2019) 2. Needham & Company LLC analysts commented, "Nabriva announced plans to acquire Zavante, a private company developing IV fosfomycin (Contepo) for the U.S. market. Zavante shareholders will receive 8.2M shares of NBRV stock and up to $97.5M in milestone payments (cash or shares) if certain regulatory/ commercial milestones are met. Although we have modest expectations for new IV antibiotics like Contepo in the hospital Gram- negative space, we believe the transaction is a net positive for Nabriva. No additional commercial infrastructure is needed beyond what is already planned for lefamulin. Zavante announced Phase 3 results 505(b)(2) submission is expected 4Q18. BUY. We recognize Nabriva needs cash, but believe lefamulin is a substantially underappreciated asset that will be relevant outside the challenging hospital setting." (7/25/2018) Has Nabriva Therapeutics been receiving favorable news coverage? News articles about NBRV stock have been trending extremely positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a daily sentiment score of 4.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. Are investors shorting Nabriva Therapeutics? Nabriva Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,004,543 shares, a decline of 59.5% from the December 14th total of 2,481,223 shares. Based on an average daily volume of 857,160 shares, the short-interest ratio is currently 1.2 days. Currently, 2.3% of the shares of the company are sold short. View Nabriva Therapeutics' Current Options Chain. Who are some of Nabriva Therapeutics' key competitors? Some companies that are related to Nabriva Therapeutics include Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND) and Blueprint Medicines (BPMC). Who are Nabriva Therapeutics' key executives? Nabriva Therapeutics' management team includes the folowing people: Mr. Steven P. Gelone, Pres & COO (Age 50)Dr. Colin Broom, Consultant & Director (Age 62)Mr. Gary L. Sender, Chief Financial Officer (Age 56)Mr. Theodore R. Schroeder, CEO & Director (Age 63)Mr. Thomas Lembck, Chief Information Officer How do I buy shares of Nabriva Therapeutics? Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $1.97. How big of a company is Nabriva Therapeutics? Nabriva Therapeutics has a market capitalization of $1.32 billion and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe. What is Nabriva Therapeutics' official website? The official website for Nabriva Therapeutics is http://www.nabriva.com. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected] MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 251 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 428MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: How is the discount rate different from the Federal Funds rate?